In course of investigating a family for another purpose, an elderly woman was found to have a high proportion of grossly damaged chromosomes. During the preceding 15 months she had been taking phenylbutazone for osteoarthrosis. She had never had any external or internal radiation therapy, and the only other drug she was taking was a 50 mg. nembutal capsule each night. As there was no obvious explanation of her chromosomal damage, and because phenylbutazone has long been suspected of occasionally causing blood dyscrasias, and possibly of being associated with leukaemia (Dougan and Woodliff, 1965) , it was decided to examine the chromosomes of a series of patients who had been taking the drug. Findings in these patients and in controls, some preliminary results from testing patients before starting to take phenylbutazone, and at intervals thereafter, and some miscellaneous observations, including experiments in vitro, form the subject of this report.
Patients studied Fifty patients, 32 women and 18 men, who had taken phenylbutazone for at least 3 months, were investigated. All except one patient were still taking the drug, or had been taking it up to a few weeks before being tested. The remaining patient (No. 12 in Appendix A) had taken the drug regularly for 3 years but not for the previous 15 years. There were also 31 control subjects who had identical chromosomal investigations. As will be seen from Appendix B, they consisted of 24 patients with rheumatic disorders who had never had phenylbutazone (with the exception noted below) and these included eight who were subsequently treated with the drug, and also seven normal subjects. No patients or controls were accepted for study if they had any history of internal or external ionizing radiation therapy or diagnostic procedures using radioisotopes. Patient No. 48 (Appendix B), after being accepted as a control, was found to have had phenylbutazone mainly by suppositories, and then only for less than 3 weeks, 21 years before being tested. However, she was retained as a control.
Cytological techniques used, types of chromosonal damage scored, and rationale of interpretation of finding Venous blood received into lithium heparin tubes was cultured for 48 hrs, using the technique of Arakaki and Sparkes (1963) . After 45 hrs, i.e. 3 hrs before harvesting the lymphocytes for chromosomal examination, colchicine was added to the culture. Chromosomes of cells in metaphase were then scored for chromosomal type damage, i.e. breaks or the sequelae of breaks.
Therationaleofthis procedurerequires someelucidation for those not conversant with cytogenetics. As is fully discussed in UNSCEAR (1969) and by Evans (1970) , it is generally accepted that, if the above type of peripheral blood culture lasting for 48 hrs is followed, chromosome type damage found in all lymphocytes in the metaphase stage of cell division must have occurred in vivo when the lymphocytes were in the GI (pre-DNA synthesis) stage of interphase. The circulating lymphocytes have a long life in vivo, probably on average about 3 years. They remain in the Gl phase and very seldom divide. However, when stimulated by phytohaemagglutinins in the culture medium, some at least, probably those which are immunopotent, proceed into a division cycle and many have reached metaphase by 45 hrs in culture. Colchicine added then stops these cells and others which subsequently reach this stage in metaphase, and they proceed no further. Any cells which have passed through metaphase by 45 hrs in culture certainly have not yet reached that stage in a second division cycle.
It follows that chromosome breaks, i.e. those affecting equally both arms of chromatids which are held together only at the centromeres in the metaphase stage, must have occurred before DNA synthesis and the formation of chromatids, i.e. in the GI stage of the cell cycle when the chromosomes were long single threads and were closely coiled in the nuclei of the lymphocytes in vivo. It follows also that chromosome type breaks and their sequelae are not caused by adverse cultural conditions; a statement which is well supported by abundant experimental evidence. In contrast, damage to chromosomes after the GI stage in culture predominantly causes chromatid type damage, as can readily be seen in experiments in vitro. This is manifest in the first metaphase after the damage by breakage of only one ofthe two chromatids (See Fig. IA ).
The origins of the types of chromosomal damage originating in vivo in GI which were scored in the cells of patients in this study are set out in diagrammatic form in Fig. 2 (opposite) .
Photographs of corresponding types of damage of chromosomes in cells of patients are shown in Fig. 1 . Additional evidence that cells have not passed through a complete cell cycle since the damage occurred in Gi is afforded by the presence of acentric fragments in the cells in metaphase. Such fragments are usually lost in anaphase and fail to be incorporated in daughter nuclei. Single breaks of a chromosome will result in a centric and an acentric fragment (Fig. IA) . If two chromosomes are broken there may simply be two centric fragments and two acentric fragments, or the broken ends of the centric fragments may unite leading to a dicentric chromosome, as in Fig. lB . There may be two acentric fragments, as in the diagram, or the two may unite to form a single larger fragment. (There are other possible explanations of there being only one fragment which need not concern us here.) As will be seen from Fig. IC , breaks on either side of the centromere may result in a centric ring and fragments. These three types of cell damage all result in cells which are unstable, are conventionally termed 'Cu', and are so classed in Tables I and II (overleaf) . They are unstable essentially because mistakes occur in anaphase and fragments are lost so that daughter cells may have a surplus; or daughter cells have a deficiency of genetic material and so be relatively inviable.
The two remaining sequelae of breaks which we need to consider here are the types whose genesis will be evident from Fig. ID and E, and it will be noted that both can follow only from two or more breaks in Gl. However, the daughter cells from these configurations will have a full chromosome complement, although abnormally arranged, and they will be viable. Such cells are, following convention, called stable and denoted as 'Cs' in Table I Complete protocols of patients are set out in Appendices A and B, so that readers have available as much information about the patients and controls as the authors.
INTERPRETATION OF THE FREQUENCIES OF DAMAGED CELLS IN PATIENTS AND CONTROLS
There is now a considerable literature on the frequency of cells with chromosomal damage in normal individuals. In published results where culture times of 50 hrs or less were used, and over 2,000 cells were analysed, estimates range from 1 32 per cent. (Court Brown, Jacobs, Buckton, Tough, Kuenssberg, and Knox, 1966) to 0-13 per cent. (Norman, 1967) . Our findings (0 48 per cent.) are just below the mean of the range. Court Brown and others (1966) considered that the frequency was significantly higher in females than in males and that it increased with age. However, when their longer (over 50 hr) culture time data is excluded, these effects are not apparent. Adams (1970) , Sandburgh, Cohen, Rimn, and Levin (1967) , and Bochkov, Koslov, Pilosov, and Sevankaev (1968) could find no such association and as noted above there appears to be none in our data (Appendix D).
The frequency of cells with dicentric chromosomes in normal individuals is usually estimated to be considerably less than 0. 1 per cent. The data reviewed in UNSCEAR (1969) ranges from 0.01 to 0O1 per cent.
All the patients with one exception had had diagnostic radiology of their joints, whereas seven of the controls did not have rheumatic disorders, and those who had arthritis or spondylitis were on averageyoungerandsohad probably had fewer radiographs. It proved impossible to collect accurate data on diagnostic radiological exposures. Some authors have suggested that after a few radiographs, mostly of the chest, patients show an increase of cells with chromosomal damage, but this has not been found by all authors (UNSCEAR, 1969; Adams, 1970) . In our own laboratory, limited investigation of the chromosomes of patients after excretion urography has yielded negative results. In any event, the differences between patients and controls in our series seem too large to be explained on a basis of past joint radiographs. In particular the frequency of dicentric chromosomes is much too high.
Other drugs taken by patients and controls A code number is given in Appendices A and B for drugs other than phenylbutazone taken by patients and controls in recent years. The key to the code will be found in Appendix C. Patients with rheumatic disorders inevitably are tried with several preparations until they find something which helps and, indeed, it proved difficult to find control patients who had not taken phenylbutazone. It is impossible adequately to set out all the details of different doses and durations for each patient. The drugs listed in the Appendices had all been taken during the 5 years prior to the test, but each for varying periods. There seems to be no pattern of association with chromosomal findings with any one drug except phenylbutazone. It will be noted that of our control patients (Appendix B) four had had at least one course of myocrysin injections, six a course of indomethacin, and four hydroxychloroquine, and three were taking preparations containing paracetamol.
Patients tested before and after takingphenylbutazone A series of patients who presented at the Rheumtism Research Centre, and for whom phenylbutazone was indicated, was tested and on the day ofcollection of the specimen began to take 100 mg. phenylbutazone (in the form of Butazolidin) three times a day. The pre-treatment specimens from eight of the patients were used as controls (Appendix B).
The preliminary results are set out in As might be expected, the proportions of controls with 0 per cent., 1 per cent., and 2 per cent. of damaged cells with a mean of 0 '48 per cent. is very closely compatible with a Poisson distribution. However, in patients taking the drug, the proportions with 0 to 9 per cent. of damaged cells with a mean of 2 per cent. is not compatible with a Poisson distribution (X2 = 16X46; d.f. = 5; P < 0X01). The reason for this is that, relative to a Poisson expectation, there is an excess of patients with less than and with more than 2 per cent. of damaged cells.
As noted earlier, the lack of correlation between the frequencies of damaged cells in patients and the accumulated dose of the drug could be interpreted as indicating that the risks of chromosomal damage had no relationship to accumulated dose. Two factors could contribute to the lack of correlation. First, the daily dose figures are probably very misleading in that patients do not follow instructions, and undoubtedly many take the drug very irregularly, and almost invariably in smaller doses than prescribed. The second possibility, not exclusive of the first, is that there is a considerable variation in different individuals of the response of their lymphocytes to a given dosage. The latter could also explain the lack of fit with a Poisson distribution.
Whittaker and Price Evans (1970) have shown that, for a given dose of phenylbutazone by body weight, the steady-state plasma level is normally distributed. The halflife ofphenylbutazone in plasma after the exhibition of barbiturates is also normally distributed and is highly correlated with the steadystate plasma level. These observations and the appropriate correlations of the two variables in first-degree relatives indicate that speed of metabolism of the drug is under genetic control and is multifactorial.
However, inherited variation in speed of metabolism of the drug need not necessarily bear any close relationship to the incidence of lymphocyte damage. Such cell damage could be determined by some breakdown product which has a higher concentration in some individuals than in others, or by some other genetic mechanism than that associated with speed of metabolism. However, nothing is known of differing breakdown pathways of the drug. There are only two metabolites of phenylbutazone to be found in the urine and they account for only some 8 per cent. of the drug ingested; 3 per cent. is contributed by a phenolic metabolite (oxyphenbutazone or 'Tanderil') and 5 per cent. by a relatively unstable alcoholic metabolite (Burns, Rose, Goodwin, Reichenthal, Homing, and Brodie, 1955) .
A high proportion of all investigations of the group.bmj.com on March 31, 2017 -Published by http://ard.bmj.com/ Downloaded from effects of other drugs and chemicals on human chromosomes has been by experiments in vitro and evidence that damage is caused in vivo is convincing only in respect of very few substances. This is partly because few observations have been made, and partly because the use of long culture times and other factors make it difficult to assess the work of certain observers who suggest that damage has occurred in vivo.
Of the alkylating agents, nitrogen mustard has definitely been shown to cause chromosomal damage in vivo (Conen and Lansky, 1961) . High chromatid damage rates and some chromosome damage have been reported in patients treated with other alkylating agents, such as piperazine (Nasjleti and Spencer, 1966) and with cyclophosphamide (Hampel, Kober, R6sch, Gerhartz, and Meinig, 1966) , but the culture times were over 48 hrs and the evidence from experiments in vitro suggests that all the agents act mainly on the 'S' or 'G2' stages of interphase, i.e. during and after DNA synthesis. Other evidence for production of chromosomal damage in vivo comes from the work of Tough and Court Brown (1965) , who found a significantly higher frequency of chromosomally damaged cells in workers exposed to ambient benzene than in controls.
Drugs which can provide base analogues for DNA, such as 5-fluorodeoxyuridine (Hampel and others, 1966) , 6-mercaptopurine (Nasjleti and Spencer, 1966), and 6-azauridine (Elves, Buttoo, Israels, and Wilkinson, 1963) , have been shown to cause chromosomal damage in vivo. The evidence that lysergic acid dimethylamide (LSD-25) causes chromosomal damage (Irwin and Egozcue, 1967; Cohen, Hirschhorn, and Frosch, 1967 ) is at present not entirely convincing. There are many other substances whose effects in vivo are not known but they have been shown to cause chromatid damage in vitro.
There are several points which may be noted concerning the drugs which are known as or suspected of causing chromosomal damage in vivo.
Most are used in the treatment of neoplasms for short periods and in near toxic doses. All also appear to cause chromatid damage in vitro. Further, when blood from patients taking the drug is cultured, not only chromosome but chromatid damage is found to be present. This is usually considered to be caused by traces of the drug in the serum affecting the 'S' or later stages in the culture medium. Nevertheless, most agents of chemical and iong radiation which break chromosomes are also carcinogenetic, although very few observers believe that this is a direct result of chromosomal breakage, thinking that it is rather the consequence of direct less well understood action on DNA. In the light of the preceding discussion, the risks of leukaemia or other neoplasia are probably not as great when phenylbutazone is the chromosome-breaking agent as with cytotoxic drugs which damage chromosomes by direct action on DNA. Possibly, as such a very large number of people take the drug in this and other countries, if the drug had definitely been leukaemogenic the phenomenon would by now be an established fact. In the United Kingdom there are at least 3,500,000 National Health Service prescriptions for phenylbutazone each year (Dunlop, 1969) . However, although the main incidence of induced chromosomal damage determines Cu cells, there must be an increase in the frequency of Cs cells as there are so many damaged cells in which more than one break occurred. In our patients the frequency of Cs cells was 15/4,298 (0 34 per cent.), which, although not significant (X2 = 2X80; P > 0 1), is about three times as great as in controls where the frequency was 3 in 3,102 (0 096 per cent.).
Cs damage is probably oflittle if any importance in somatic cells and it may be suspected from the evidence presented above that phenylbutazone would not damage chromosomes of oocytes, which are in the special stage of the first meiotic division where they have passed the DNA synthesis stage. However, in the male, there is a constant pool of type A spermatogonia where chromosomal damage of both the Cu and Cs type could accumulate. These could give rise to viable sperm which were unbalanced in chromosome constitution and cause peri-implantation losses of zygotes or surviving deformed foetuses. Spermatogonia with Cs reciprocal translocations would be expected to permit a higher proportion of zygotes to survive to become maldeveloped foetuses than viable Cu cells with small deletions.
The overall frequency of children recognized as suffering from the effect of an unbalanced translocation is very low, perhaps not more than 1 in 5,000, but in view of the difficulty in identifying small differences and sizes of chromosomes, unidentified but biologically important translocations must be several times as frequent as those recognized. Nevertheless, the risk to the offspring of a male taking phenylbutazone, although still low, is probably several times above the mean in the population. The amount of chromosome damage is less by an order of magnitude in patients with ankylosing spondylitis taking phenylbutazone than in those treated by deep x-ray therapy of the spine. Nevertheless, very large numbers of patients take the drug and if another can be employed which will keep young patients, particularly males, comfortable, it would seem wise to use it. In the light of the suggestive evidence of individual variation, it would probably be wise, in young patients, to examine their chromosomes after 3 months of treatment.
There are a number ofindications for further work, and some of these are being followed in various laboratories. Our findings in vitro are not conclusive and the situation in vitro must be clarified. This sounds simple, but there are many snags in the planning, control, and interpretation of experiments in vitro. The search for the induction of chromosomal abnormalities in spermatogonia of experimental animals should be pursued, using the 'dominant lethals' technique. There are problems to be overcome in such experiments. The half-life of the drug in mice and other small animals is a matter of hours and it is difficult to arrange for high plasma levels to be maintained over the considerable period of time which, by analogy with our findings, would be necessary if many chromosome breaks were to be induced. 
